1. Medtech Insight
  2. >>Business
  3. >>Deals

Edwards To Pay Up To $690m For Cardioband-Maker Valtech

 
• By Reed Miller

The Cardioband system is a transcatheter annuloplasty device for repair of mitral and tricuspid valves that should be a natural fit with Edwards transcatheter mitral valve development program. Israel-based Valtech had a deal in September 2015 to be acquired by HeartWare for $900m, but that deal fell through after HeartWare investors protested.

Valtech's Cardioband mitral repair system • Source: SOURCE: Edwards Lifesciences

Edwards Lifesciences Corp. has agreed to pay $340m in stock and cash up front and up to $350m more in milestone payments for Valtech Cardio Ltd., the developer of the Cardioband transcatheter mitral valve repair technology that can also be adapted to repair tricuspid valves.

"We saw an important opportunity to incorporate Valtech's technologies into our comprehensive heart valve repair and replacement portfolio," Edwards CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 
• By Natasha Barrow

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

More from Business

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.